Literature DB >> 16943578

Antisense p53 decreases production of VEGF in follicular thyroid cancer cells.

I Hassan1, A Wunderlich, E Slater, S Hoffmann, I Celik, A Zielke.   

Abstract

Inactivating mutations of wild-type p53 (WTp53) tumor suppressor gene are common in anaplastic thyroid cancer (ATC) and are associated with poor prognosis. Mutated p53 (MTp53) has been implicated with angiogenesis. Therefore, the potential of MTp53 knockout by oligodeoxyribonucleotide phosphorothioates (ODNs) to affect VEGF production of undifferentiated thyroid cancer cells with a recessive MTp53 mutation was evaluated. Transient transfection with 20 bp ODNs complementary to portions of exon 10 of p53 and a negative control ODN (HIV-RT) were carried out in FTC-133 cells. In vitro secretion of VEGF protein was quantified by EIA and correlated to cell numbers, which was evaluated by in vitro MTT assay. Transfection of undifferentiated thyroid cancer cells with ODN reduced VEGF secretion of FTC-133 cells following transfection by 34% as compared to the negative control (cells transfected with ODN-HIV; p = 0.03). These results suggest that transient MTp53 knockout with ODNs complementary to p53 nucleotide sequences impair secretion of VEGF in the undifferentiated thyroid cancer cell line FTC-133.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16943578     DOI: 10.1385/ENDO:29:3:409

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  18 in total

1.  Loss of p53 promotes anaplasia and local invasion in ret/PTC1-induced thyroid carcinomas.

Authors:  K M La Perle; S M Jhiang; C C Capen
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

Review 2.  How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes memorial Award lecture.

Authors:  J Folkman
Journal:  Cancer Res       Date:  1986-02       Impact factor: 12.701

3.  Antiproliferative effect of suramin on primary cultures of human pheochromocytomas and rat PC12 pheochromocytoma cells.

Authors:  A Zielke; M G Wong; A E Siperstein; O H Clark; M Rothmund; Q Y Duh
Journal:  J Surg Oncol       Date:  1997-09       Impact factor: 3.454

4.  Inhibition of angiogenesis and tumorigenesis, and induction of dormancy by p53 in a p53-null thyroid carcinoma cell line in vivo.

Authors:  Y Nagayama; K Shigematsu; H Namba; K Zeki; S Yamashita; M Niwa
Journal:  Anticancer Res       Date:  2000 Jul-Aug       Impact factor: 2.480

5.  Selective cytotoxicity to human leukemic myeloblasts produced by oligodeoxyribonucleotide phosphorothioates complementary to p53 nucleotide sequences.

Authors:  E Bayever; K M Haines; P L Iversen; R W Ruddon; S J Pirruccello; C P Mountjoy; M A Arneson; L J Smith
Journal:  Leuk Lymphoma       Date:  1994-01

6.  Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid.

Authors:  E Y Soh; Q Y Duh; S A Sobhi; D M Young; H D Epstein; M G Wong; Y K Garcia; Y D Min; R F Grossman; A E Siperstein; O H Clark
Journal:  J Clin Endocrinol Metab       Date:  1997-11       Impact factor: 5.958

7.  Vascular endothelial growth factor monoclonal antibody inhibits growth of anaplastic thyroid cancer xenografts in nude mice.

Authors:  Andrew J Bauer; Richard Terrell; Nalinikrishna K Doniparthi; Aneeta Patel; R Michael Tuttle; Motoyasu Saji; Matthew D Ringel; Gary L Francis
Journal:  Thyroid       Date:  2002-11       Impact factor: 6.568

8.  Therapeutic usefulness of wild-type p53 gene introduction in a p53-null anaplastic thyroid carcinoma cell line.

Authors:  M Narimatsu; Y Nagayama; K Akino; M Yasuda; T Yamamoto; T T Yang; A Ohtsuru; H Namba; S Yamashita; H Ayabe; M Niwa
Journal:  J Clin Endocrinol Metab       Date:  1998-10       Impact factor: 5.958

9.  Growth inhibition of pancreatic tumor cells by modified antisense oligodeoxynucleotides.

Authors:  A Fiedler; C Knorre; Y Franke; D Henne-Bruns; B Kremer; J Lüttges; M Maier; M Gerster; K Bleicher; E Bayer; H Kalthoff
Journal:  Langenbecks Arch Surg       Date:  1998-08       Impact factor: 3.445

10.  Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1.

Authors:  K M Dameron; O V Volpert; M A Tainsky; N Bouck
Journal:  Science       Date:  1994-09-09       Impact factor: 47.728

View more
  3 in total

1.  VEGF and GM-CSF levels in nodular thyroid diseases.

Authors:  Birsen Bilgici; Gulcin C Ecemis; Ozgur K Tuncel; Ilkay K Bayrak; Elif K Kan; Aysegul Atmaca
Journal:  Endocrine       Date:  2013-04-28       Impact factor: 3.633

2.  Involvement of transcription factor p53 and leptin in control of porcine ovarian granulosa cell functions.

Authors:  A V Sirotkin; A Benčo; A Tandlmajerová; D Vašíček
Journal:  Cell Prolif       Date:  2011-12-07       Impact factor: 6.831

3.  Geographical mapping of a multifocal thyroid tumour using genetic alteration analysis & miRNA profiling.

Authors:  Sinéad T Aherne; Paul C Smyth; Richard J Flavin; Susan M Russell; Karen M Denning; Jing Huan Li; Simone M Guenther; John J O'Leary; Orla M Sheils
Journal:  Mol Cancer       Date:  2008-12-04       Impact factor: 27.401

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.